How We Measure TPE Results: The Labs Behind Every Session

Most TPE clinics perform the procedure and send you home. At Liondale, every session is bracketed by a pre-treatment baseline draw and a post-treatment follow-up panel. We measure the same markers before and after: CRP, IL-6, fibrinogen, a metabolic panel, a lipid panel, and where clinically relevant, epigenetic clock biomarkers. The point is simple - you should know whether the intervention moved something, not just whether you felt different the next morning. Dr. Bissoon reviews every result personally before your next session is planned, because a premium procedure should produce more than a vague sense that maybe it helped.

If you want the broader overview first, start with our Therapeutic Plasma Exchange service page. If cost is your first filter, read our TPE cost in NYC guide. This page is narrower. It is about measurement.

Why Tracking Changes Everything

TPE is not cheap. When a procedure lives in the $10,000-and-up world, the standard cannot be, "How did you feel the next day?" That matters, of course, but it is not enough. Tracking turns an expensive intervention into a feedback loop. Without that loop, you are paying for an experience and hoping it translated into an outcome.

With labs, the conversation changes. Did inflammatory burden actually shift? Did CRP drop, or stay flat? Did IL-6 calm down, or was the cytokine picture basically unchanged? Did fibrinogen move the way we expected after plasma exchange? And if the markers do move, how long does that effect hold before the next session should be considered? Those questions determine frequency, whether IVIG belongs in the plan, whether another therapy should be layered in, and sometimes whether we should stop.

That is where many clinics separate themselves. The soft version of longevity medicine asks, "Do you feel more energized?" The harder version asks, "What did your CRP do?" Those are different standards. I prefer the second one.

And there is another reason tracking matters: it protects the patient from autopilot care. If the numbers are not moving, we do not keep repeating the same script because it is convenient for the clinic. We change the plan. Or we pause it. Good medicine has an off-ramp.

The Pre-Treatment Baseline - What We Draw and Why

Before the first session, we draw a full baseline panel. This is not paperwork disguised as medicine. It tells us what kind of inflammatory picture a patient is bringing into treatment, whether the organs handling fluid and metabolic stress look steady, and whether the person in front of us is actually a sensible TPE candidate. But the baseline also does something more practical: it gives us a fair starting line. Without that, every "improvement" claim is mushy.

• CRP (C-reactive protein): a broad marker of systemic inflammation. It can rise with acute illness, chronic inflammatory load, metabolic dysfunction, poor recovery, and a long list of other stressors. That broadness is exactly why it is useful at baseline.
• IL-6 (interleukin-6): a pro-inflammatory cytokine that sits further upstream than CRP and helps drive acute-phase responses. When IL-6 is elevated, I pay attention, because it can tell us the inflammatory signal is still actively being generated rather than merely leaving residue behind.
• Fibrinogen: an acute-phase protein involved in both inflammation and coagulation. It matters in TPE because it is not just an inflammatory clue. It is also part of the clotting system, which means interpretation has to be more careful.
• Metabolic panel: glucose, liver enzymes such as ALT and AST, kidney function markers such as creatinine, BUN, and eGFR, plus electrolytes. This tells us whether the system looks stable before we start moving fluid through an extracorporeal circuit.
• Lipid panel: total cholesterol, LDL, HDL, and triglycerides. This does not tell the whole longevity story, but it helps us place inflammatory markers inside a broader cardiometabolic frame.
• Epigenetic clock biomarkers, where clinically relevant: DNA methylation-based biological age estimates. These are not standard for every patient. We add them when tracking biological age response is part of the reason the patient is pursuing TPE in the first place.

This baseline also functions as candidacy screening. If the pattern is not what I would expect in a patient likely to benefit from TPE, that changes the conversation before any session is booked. Sometimes the issue is untreated metabolic dysfunction. Sometimes it is a more obvious inflammatory driver. Sometimes the problem is simpler: the patient wants TPE because it sounds advanced, but the real first move is still basic medical housekeeping. That honesty saves people money.

For a deeper look at who is and is not a fit, read our TPE safety and candidacy guide. That page covers the front-end screen. This page covers what happens once we decide to proceed.

The Post-Treatment Follow-Up Panel

After each session, we repeat the same core markers. Same logic. Same scoreboard. If you change the labs every time, you lose the thread. We want apples-to-apples comparisons, not a shifting set of numbers that lets everyone tell themselves a flattering story.

What does a useful response look like? CRP trends toward a better range. IL-6 comes down. Fibrinogen drops as expected, then restores in a pattern that makes physiologic sense. The metabolic panel stays stable or improves, which reassures us the procedure is being tolerated cleanly. And when epigenetic clock biomarkers are part of the plan, we want movement in the direction the 2025 Aging Cell trial made so interesting.

What does a non-response look like? One number improves while the rest of the picture does not. Or a marker dips once, then snaps right back. Or the patient feels terrific for 36 hours, but the lab picture is stubbornly unchanged. A partial signal still matters. It just is not the same thing as proof that the protocol is dialed in.

But I would rather see an inconvenient result than a comforting fiction. If the data says we need to rethink frequency, IVIG timing, or candidacy itself, that is valuable information. False reassurance is not.

What Each Marker Tells Us in a TPE Context

CRP

CRP is the broad inflammation signal. It is not specific, and that is both its weakness and its strength. It can rise because of infection, metabolic strain, visceral adiposity, poor sleep, autoimmune activity, hard training, dental inflammation, or a dozen other things. So no, a CRP result never speaks alone. But in elective longevity TPE, I still want it on the page because it gives us a fast read on whether the total inflammatory burden looks different after treatment.

The part many patients miss is this: normal and optimal are not the same target. A laboratory may call a CRP under 10 mg/L "normal." That does not mean it is where I want a high-functioning 55-year-old executive, athlete, or prevention-focused patient to live. The question is not, "Did you stay inside the lab's broad reference range?" The question is, "Did you move toward a better biologic state?" Short version: reference range medicine and longevity medicine do not always aim at the same line.

IL-6

IL-6 gives us a more upstream view. CRP is often the downstream smoke. IL-6 can help show where the fire is being driven. It rises quickly in acute inflammation and can remain elevated in chronic inflammatory states, metabolic dysfunction, immune dysregulation, and other scenarios that matter in a TPE population. When IL-6 falls after treatment, that suggests we may be changing more than a downstream acute-phase protein. We may be changing the signaling environment itself.

That matters because it helps separate cosmetic lab improvement from deeper physiologic movement. If CRP improves but IL-6 remains sticky, I do not declare victory. I ask what is still feeding the signal. Infection? Autoimmune activity? Adipose-driven inflammation? Recovery issues? Something else? This is where lab interpretation becomes clinical judgment, not just spreadsheet work.

Fibrinogen

Fibrinogen is the dual-role marker. It is part inflammatory marker, part clotting factor. In a TPE context, that dual role is useful because plasma exchange physically removes fibrinogen along with many other plasma proteins, so a post-treatment drop is expected. The real question is not whether it fell. The real question is how it restores, how fast, and to what level.

If fibrinogen rebounds quickly to an unfavorable baseline, that tells me the inflammatory and coagulation story underneath the procedure may still be active. If it restores more calmly into a better range, that is a different story. And because fibrinogen has implications beyond "inflammation" as a vague label, it is one of the markers I do not like to discuss casually. Numbers have context.

Metabolic panel

The metabolic panel is less glamorous, but it is essential. TPE involves fluid shifts, vascular access, anticoagulation management, and time connected to an extracorporeal system. I want to know that the kidneys are handling it well, that the liver picture remains steady, that glucose is not telling us a different metabolic story in the background, and that electrolytes are where they should be. Fancy longevity medicine still needs boring safety data. Especially when it is elective.

This panel also keeps us honest about what TPE is and is not doing. If someone expects plasma exchange to fix every piece of a messy metabolic picture, disappointment is coming. TPE can change part of the terrain. It does not erase poor sleep, insulin resistance, heavy alcohol use, or an untreated endocrine issue. That is why I look at these numbers as tolerance markers and context markers, not as a miracle ledger.

Lipid panel

The lipid panel helps frame the cardiometabolic side of the case. Total cholesterol, LDL, HDL, and triglycerides are not direct stand-ins for inflammatory burden, but they do tell us something about the broader physiology the patient is living in. If a person has elevated inflammatory markers and a lipid pattern that also points toward metabolic strain, that carries a different implication than isolated inflammation in an otherwise clean picture.

And that matters when we decide what TPE is supposed to accomplish. Is it being used as a focused intervention inside an otherwise disciplined prevention plan? Or is it being asked to carry far more weight than it should? Labs can answer that if you are willing to look straight at them.

Epigenetic clock biomarkers

Epigenetic clocks are DNA methylation-based estimates of biological age. They are interesting. They are useful. They are also not the same thing as a clinical diagnosis. I want to be clear about that because this is where longevity clinics sometimes get sloppy.

We use these biomarkers when they are relevant to the patient's goal, particularly when the patient is pursuing TPE because of the emerging biological-age literature rather than only symptom burden or inflammatory tracking. The reason they matter is obvious: the 2025 Aging Cell trial put real numbers on biological age change after TPE, and that gave the field something better than hand-waving. If you want the evidence breakdown, read our clinical trial evidence page.

But here is the caveat I always give. An epigenetic clock can move in the right direction and still not answer every practical question a patient cares about. It does not tell you whether you will sleep better next week. It does not prove lifespan extension. It does not replace a metabolic panel, an inflammatory panel, or common sense. It is a research-grade lens, not a magic mirror.

When Markers Don't Move - What Happens

This is the section most clinics avoid, which is exactly why it matters. If CRP has not moved after session 2, I want to know why. Not in theory. In that patient. If IL-6 is unchanged, or fibrinogen keeps returning to the same bad neighborhood, that is not a footnote. That is the case.

This is where clinics tell on themselves

A weak clinic response is to keep selling sessions and call it a long-term process. I do not like that answer. A stronger response is to ask the hard questions. Was session frequency too low to sustain the clearance effect? Was IVIG timing wrong for the physiology we are seeing? Is there an underlying inflammatory driver, such as infection, autoimmune activity, or metabolic dysfunction, that TPE is not going to solve by itself? And sometimes the answer is uncomfortable: this patient may not be the right fit for TPE at this stage.

Once that review happens, there are several possible moves. We may increase frequency for a defined interval. We may reconsider whether IVIG belongs in the plan. We may add a complementary therapy, such as NAD+, ozone, or hormone work, if the broader picture supports that choice. We may pause and reassess instead of forcing momentum that the data has not earned.

But the answer is never to keep running sessions that the numbers do not support. That is not personalized medicine. That is inertia with a luxury price tag.

Patients appreciate directness here. They should. If you are investing heavily in a physician-supervised program, you deserve an honest answer when the physiology is underwhelming. No spin.

Kevin MacDonald - What "Moving Into the Green" Actually Means

"Watching all my bloodwork numbers move into or towards the green gives me a lot of confidence in what I'm doing with TPE."

- Kevin MacDonald, age 63, Circulate Health patient

I like that quote because it says exactly what patients should want from a treatment like this: not hype, not mystery, not the vague thrill of doing something expensive. Movement. Measured movement.

And "into the green" does not just mean into the lab's normal range. For a high-functioning 63-year-old trying to preserve performance, normal CRP and optimal CRP are not the same thing. Under 10 mg/L may keep a result out of the red. Under 1 mg/L is a very different target. That is why Liondale's lab tracking is oriented toward what is better, not merely what escapes the abnormal flag.

If you want to understand why Liondale built the program this way, read why patients choose Liondale for TPE in NYC. The short answer is simple: physician review, concierge follow-through, and a stricter standard for what counts as a result.

FAQ

Which labs are included with my session?

Each session is tied to the same core lab framework: CRP, IL-6, fibrinogen, a metabolic panel, and a lipid panel. Where clinically relevant, Dr. Bissoon may also include epigenetic clock biomarkers to track biological age response. The point is consistency. We want to compare like with like from session to session.

When is the post-treatment draw done?

The post-treatment panel is done after each session as part of the follow-up plan. Exact timing can vary based on the marker we are watching and the protocol being used, but the principle does not change: we do not wait months and guess. We measure the response in a clinically useful window.

What if my markers don't improve after treatment?

Then we do not pretend they did. Dr. Bissoon reviews the pattern and decides whether the next move is a frequency change, an IVIG adjustment, a complementary treatment, or a pause. If the data does not support continuing on the same path, we say that directly.

Do I need to fast before the lab draw?

Sometimes, yes, especially when the lipid panel is part of the interpretation we care about most. But not every draw is handled the same way. You will get specific prep instructions before your visit so the numbers are actually usable instead of technically collected but clinically noisy.

Can I see my lab results directly?

Yes. You should be able to see what was measured and how it changed. These labs are part of your care, not a private scorecard for the clinic. We review them with you so the numbers make sense in context, and we use them to guide what happens next.

Does Liondale track epigenetic age?

Yes, when it is relevant to the clinical goal. Epigenetic age testing is not necessary for every patient pursuing TPE, but it can be useful when the purpose of treatment is closely tied to biological age tracking and response over time. It is one tool, not the whole story.

If you are considering treatment and want to talk through the lab process before booking, you can contact Liondale Medical. Some patients also read our safety and candidacy guide and the main TPE service page first, which is usually a smart place to start.

This article was written and reviewed by Lionel Bissoon, D.O., founder of Liondale Medical. Dr. Bissoon is a board-certified osteopathic physician specializing in anti-aging and concierge medicine on the Upper West Side of Manhattan. Liondale Medical is a Circulate Health partner.

This content is for educational purposes only and does not constitute medical advice. Individual results may vary. Consult a qualified physician before beginning any new treatment.